PanCareSurPass Project HL7 FHIR Implementation Guide
0.2.0 - CI Build
150
PanCareSurPass Project HL7 FHIR Implementation Guide
0.2.0 - CI Build
150
PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 0.2.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions
| Draft as of 2024-12-11 |
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:CodeSystem ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "cs-riskfactor-eu-pcsp"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem cs-riskfactor-eu-pcsp</b></p><a name=\"cs-riskfactor-eu-pcsp\"> </a><a name=\"hccs-riskfactor-eu-pcsp\"> </a><a name=\"cs-riskfactor-eu-pcsp-en-US\"> </a><p>This case-sensitive code system <code>http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">1.1<a name=\"cs-riskfactor-eu-pcsp-1.461\"> </a></td><td>RT to a vol exposing the thyroid gland</td><td>RT to a vol exposing the thyroid gland</td></tr><tr><td style=\"white-space:nowrap\">1.2<a name=\"cs-riskfactor-eu-pcsp-1.462\"> </a></td><td>TBI</td><td>TBI</td></tr><tr><td style=\"white-space:nowrap\">1.3<a name=\"cs-riskfactor-eu-pcsp-1.463\"> </a></td><td>MIBG therapy (I-131 MIBG therapy)</td><td>MIBG therapy (I-131 MIBG therapy)</td></tr><tr><td style=\"white-space:nowrap\">2.1<a name=\"cs-riskfactor-eu-pcsp-2.461\"> </a></td><td>RT >= 10 Gy to a vol exposing the breasts</td><td>RT >= 10 Gy to a vol exposing the breasts</td></tr><tr><td style=\"white-space:nowrap\">2.2<a name=\"cs-riskfactor-eu-pcsp-2.462\"> </a></td><td>OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age</td><td>OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age</td></tr><tr><td style=\"white-space:nowrap\">3.1<a name=\"cs-riskfactor-eu-pcsp-3.461\"> </a></td><td>RT >= 35 Gy to a vol exposing the heart</td><td>RT >= 35 Gy to a vol exposing the heart</td></tr><tr><td style=\"white-space:nowrap\">3.2<a name=\"cs-riskfactor-eu-pcsp-3.462\"> </a></td><td>Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2</td><td>Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">3.3<a name=\"cs-riskfactor-eu-pcsp-3.463\"> </a></td><td>RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2</td><td>RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">4.1<a name=\"cs-riskfactor-eu-pcsp-4.461\"> </a></td><td>Alkylating agents</td><td>Alkylating agents</td></tr><tr><td style=\"white-space:nowrap\">4.2<a name=\"cs-riskfactor-eu-pcsp-4.462\"> </a></td><td>RT to a vol exposing the testes</td><td>RT to a vol exposing the testes</td></tr><tr><td style=\"white-space:nowrap\">4.3<a name=\"cs-riskfactor-eu-pcsp-4.463\"> </a></td><td>Including TBI</td><td>Including TBI</td></tr><tr><td style=\"white-space:nowrap\">5.1<a name=\"cs-riskfactor-eu-pcsp-5.461\"> </a></td><td>RT >=12 Gy to a vol exposing the testicles</td><td>RT >=12 Gy to a vol exposing the testicles</td></tr><tr><td style=\"white-space:nowrap\">6.3<a name=\"cs-riskfactor-eu-pcsp-6.463\"> </a></td><td>Surgery to the spinal cord, sympathetic nerves or pelvis</td><td>Surgery to the spinal cord, sympathetic nerves or pelvis</td></tr><tr><td style=\"white-space:nowrap\">6.4<a name=\"cs-riskfactor-eu-pcsp-6.464\"> </a></td><td>Hypogonadal</td><td>Hypogonadal</td></tr><tr><td style=\"white-space:nowrap\">7.2<a name=\"cs-riskfactor-eu-pcsp-7.462\"> </a></td><td>RT to a vol exposing the ovaries</td><td>RT to a vol exposing the ovaries</td></tr><tr><td style=\"white-space:nowrap\">8.1<a name=\"cs-riskfactor-eu-pcsp-8.461\"> </a></td><td>RT >= 30 Gy to a vol exposing the head or the brain</td><td>RT >= 30 Gy to a vol exposing the head or the brain</td></tr><tr><td style=\"white-space:nowrap\">8.2<a name=\"cs-riskfactor-eu-pcsp-8.462\"> </a></td><td>Cisplatin (with or without carboplatin > 1500 mg/m2)</td><td>Cisplatin (with or without carboplatin > 1500 mg/m2)</td></tr><tr><td style=\"white-space:nowrap\">9.1<a name=\"cs-riskfactor-eu-pcsp-9.461\"> </a></td><td>RT to a vol exposing the pancreas</td><td>RT to a vol exposing the pancreas</td></tr><tr><td style=\"white-space:nowrap\">10.2<a name=\"cs-riskfactor-eu-pcsp-10.462\"> </a></td><td>HSCT</td><td>HSCT</td></tr><tr><td style=\"white-space:nowrap\">11.1<a name=\"cs-riskfactor-eu-pcsp-11.461\"> </a></td><td>RT to a volume exposing the hypothalamus or pituatary gland</td><td>RT to a volume exposing the hypothalamus or pituatary gland</td></tr><tr><td style=\"white-space:nowrap\">11.3<a name=\"cs-riskfactor-eu-pcsp-11.463\"> </a></td><td>Hypothalamic or pituitary tumour</td><td>Hypothalamic or pituitary tumour</td></tr><tr><td style=\"white-space:nowrap\">11.4<a name=\"cs-riskfactor-eu-pcsp-11.464\"> </a></td><td>Neurosurgery of the hypothalamus or pituitary gland</td><td>Neurosurgery of the hypothalamus or pituitary gland</td></tr><tr><td style=\"white-space:nowrap\">12.1<a name=\"cs-riskfactor-eu-pcsp-12.461\"> </a></td><td>RT to a vol exposing the kidneys, heart and associated large vessels</td><td>RT to a vol exposing the kidneys, heart and associated large vessels</td></tr><tr><td style=\"white-space:nowrap\">12.3<a name=\"cs-riskfactor-eu-pcsp-12.463\"> </a></td><td>Nephrectomy</td><td>Nephrectomy</td></tr><tr><td style=\"white-space:nowrap\">12.4<a name=\"cs-riskfactor-eu-pcsp-12.464\"> </a></td><td>Ifosfamide</td><td>Ifosfamide</td></tr><tr><td style=\"white-space:nowrap\">12.5<a name=\"cs-riskfactor-eu-pcsp-12.465\"> </a></td><td>Platinium based chemotherapy</td><td>Platinium based chemotherapy</td></tr><tr><td style=\"white-space:nowrap\">12.6<a name=\"cs-riskfactor-eu-pcsp-12.466\"> </a></td><td>Nitrosureas</td><td>Nitrosureas</td></tr><tr><td style=\"white-space:nowrap\">12.7<a name=\"cs-riskfactor-eu-pcsp-12.467\"> </a></td><td>Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)</td><td>Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)</td></tr><tr><td style=\"white-space:nowrap\">13.1<a name=\"cs-riskfactor-eu-pcsp-13.461\"> </a></td><td>Cranial and/or spinal RT</td><td>Cranial and/or spinal RT</td></tr><tr><td style=\"white-space:nowrap\">13.3<a name=\"cs-riskfactor-eu-pcsp-13.463\"> </a></td><td>Methotrexate</td><td>Methotrexate</td></tr><tr><td style=\"white-space:nowrap\">13.4<a name=\"cs-riskfactor-eu-pcsp-13.464\"> </a></td><td>Gonadal failure</td><td>Gonadal failure</td></tr><tr><td style=\"white-space:nowrap\">13.5<a name=\"cs-riskfactor-eu-pcsp-13.465\"> </a></td><td>Growth hormone deficiency</td><td>Growth hormone deficiency</td></tr><tr><td style=\"white-space:nowrap\">13.6<a name=\"cs-riskfactor-eu-pcsp-13.466\"> </a></td><td>Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment</td><td>Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment</td></tr><tr><td style=\"white-space:nowrap\">13.7<a name=\"cs-riskfactor-eu-pcsp-13.467\"> </a></td><td>HSCT, especially with an history of GVHD</td><td>HSCT, especially with an history of GVHD</td></tr><tr><td style=\"white-space:nowrap\">14.3<a name=\"cs-riskfactor-eu-pcsp-14.463\"> </a></td><td>High dose RT</td><td>High dose RT</td></tr><tr><td style=\"white-space:nowrap\">15.1<a name=\"cs-riskfactor-eu-pcsp-15.461\"> </a></td><td>Radiotherapy to a vol exposing the HP region >= 30 Gy</td><td>Radiotherapy to a vol exposing the HP region >= 30 Gy</td></tr><tr><td style=\"white-space:nowrap\">15.2<a name=\"cs-riskfactor-eu-pcsp-15.462\"> </a></td><td>Surgery near or within the HP region</td><td>Surgery near or within the HP region</td></tr><tr><td style=\"white-space:nowrap\">15.3<a name=\"cs-riskfactor-eu-pcsp-15.463\"> </a></td><td>CNS tumours near or within the HP region</td><td>CNS tumours near or within the HP region</td></tr><tr><td style=\"white-space:nowrap\">16.1<a name=\"cs-riskfactor-eu-pcsp-16.461\"> </a></td><td>Radiotherapy to a vol exposing the HP region< 30 Gy</td><td>Radiotherapy to a vol exposing the HP region< 30 Gy</td></tr><tr><td style=\"white-space:nowrap\">16.2<a name=\"cs-riskfactor-eu-pcsp-16.462\"> </a></td><td>Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)</td><td>Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)</td></tr><tr><td style=\"white-space:nowrap\">17.1<a name=\"cs-riskfactor-eu-pcsp-17.461\"> </a></td><td>Radiotherapy to a vol exposing the HP region</td><td>Radiotherapy to a vol exposing the HP region</td></tr><tr><td style=\"white-space:nowrap\">17.5<a name=\"cs-riskfactor-eu-pcsp-17.465\"> </a></td><td>hydrocephalus or cerebrospinal fluid shunt</td><td>hydrocephalus or cerebrospinal fluid shunt</td></tr><tr><td style=\"white-space:nowrap\">19.3<a name=\"cs-riskfactor-eu-pcsp-19.463\"> </a></td><td>Radioiodine therapy (I-131 ablation therapy)</td><td>Radioiodine therapy (I-131 ablation therapy)</td></tr><tr><td style=\"white-space:nowrap\">19.5<a name=\"cs-riskfactor-eu-pcsp-19.465\"> </a></td><td>Allogenic HSCT</td><td>Allogenic HSCT</td></tr><tr><td style=\"white-space:nowrap\">19.6<a name=\"cs-riskfactor-eu-pcsp-19.466\"> </a></td><td>Total thyroidectomy</td><td>Total thyroidectomy</td></tr><tr><td style=\"white-space:nowrap\">20.1<a name=\"cs-riskfactor-eu-pcsp-20.461\"> </a></td><td>RT to a vol exposing the head, brain or neck</td><td>RT to a vol exposing the head, brain or neck</td></tr><tr><td style=\"white-space:nowrap\">21.1<a name=\"cs-riskfactor-eu-pcsp-21.461\"> </a></td><td>History of a central nervous system tumor</td><td>History of a central nervous system tumor</td></tr><tr><td style=\"white-space:nowrap\">21.2<a name=\"cs-riskfactor-eu-pcsp-21.462\"> </a></td><td>RT to a vol exposing the brain ANY DOSE</td><td>RT to a vol exposing the brain ANY DOSE</td></tr><tr><td style=\"white-space:nowrap\">21.4<a name=\"cs-riskfactor-eu-pcsp-21.464\"> </a></td><td>Brain surgery</td><td>Brain surgery</td></tr><tr><td style=\"white-space:nowrap\">21.5<a name=\"cs-riskfactor-eu-pcsp-21.465\"> </a></td><td>High dose cytarabine IV (intravenous)</td><td>High dose cytarabine IV (intravenous)</td></tr><tr><td style=\"white-space:nowrap\">21.6<a name=\"cs-riskfactor-eu-pcsp-21.466\"> </a></td><td>High dose MTX IV</td><td>High dose MTX IV</td></tr><tr><td style=\"white-space:nowrap\">21.7<a name=\"cs-riskfactor-eu-pcsp-21.467\"> </a></td><td>Any Chemotherapy IT (intrathecal)</td><td>Any Chemotherapy IT (intrathecal)</td></tr><tr><td style=\"white-space:nowrap\">22.1<a name=\"cs-riskfactor-eu-pcsp-22.461\"> </a></td><td>Vinca-Alkaloids</td><td>Vinca-Alkaloids</td></tr><tr><td style=\"white-space:nowrap\">22.2<a name=\"cs-riskfactor-eu-pcsp-22.462\"> </a></td><td>Cisplatin or carboplatin</td><td>Cisplatin or carboplatin</td></tr><tr><td style=\"white-space:nowrap\">23.1<a name=\"cs-riskfactor-eu-pcsp-23.461\"> </a></td><td>RT to a vol exposing the lens</td><td>RT to a vol exposing the lens</td></tr><tr><td style=\"white-space:nowrap\">24.1<a name=\"cs-riskfactor-eu-pcsp-24.461\"> </a></td><td>RT to a vol exposing the eye and orbit</td><td>RT to a vol exposing the eye and orbit</td></tr><tr><td style=\"white-space:nowrap\">25.1<a name=\"cs-riskfactor-eu-pcsp-25.461\"> </a></td><td>RT to a vol exposing the craniofacial area, especially after high doses and at a young age</td><td>RT to a vol exposing the craniofacial area, especially after high doses and at a young age</td></tr><tr><td style=\"white-space:nowrap\">25.3<a name=\"cs-riskfactor-eu-pcsp-25.463\"> </a></td><td>Surgery to the face, especially at a young age</td><td>Surgery to the face, especially at a young age</td></tr><tr><td style=\"white-space:nowrap\">26.1<a name=\"cs-riskfactor-eu-pcsp-26.461\"> </a></td><td>Surgery of the spine</td><td>Surgery of the spine</td></tr><tr><td style=\"white-space:nowrap\">26.2<a name=\"cs-riskfactor-eu-pcsp-26.462\"> </a></td><td>Surgery of the chest (Does not include CVC pose)</td><td>Surgery of the chest (Does not include CVC pose)</td></tr><tr><td style=\"white-space:nowrap\">26.3<a name=\"cs-riskfactor-eu-pcsp-26.463\"> </a></td><td>RT to a vol exposing the spine</td><td>RT to a vol exposing the spine</td></tr><tr><td style=\"white-space:nowrap\">26.4<a name=\"cs-riskfactor-eu-pcsp-26.464\"> </a></td><td>Spinal or paraspinal malignancies</td><td>Spinal or paraspinal malignancies</td></tr><tr><td style=\"white-space:nowrap\">27.1<a name=\"cs-riskfactor-eu-pcsp-27.461\"> </a></td><td>Cyclophosphamide</td><td>Cyclophosphamide</td></tr><tr><td style=\"white-space:nowrap\">27.3<a name=\"cs-riskfactor-eu-pcsp-27.463\"> </a></td><td>RT to a vol exposing the bladder</td><td>RT to a vol exposing the bladder</td></tr><tr><td style=\"white-space:nowrap\">27.5<a name=\"cs-riskfactor-eu-pcsp-27.465\"> </a></td><td>Cystectomy</td><td>Cystectomy</td></tr><tr><td style=\"white-space:nowrap\">27.6<a name=\"cs-riskfactor-eu-pcsp-27.466\"> </a></td><td>Hysterectomy</td><td>Hysterectomy</td></tr><tr><td style=\"white-space:nowrap\">27.7<a name=\"cs-riskfactor-eu-pcsp-27.467\"> </a></td><td>Pelvic surgery</td><td>Pelvic surgery</td></tr><tr><td style=\"white-space:nowrap\">27.8<a name=\"cs-riskfactor-eu-pcsp-27.468\"> </a></td><td>Spinal cord surgery</td><td>Spinal cord surgery</td></tr><tr><td style=\"white-space:nowrap\">28.1<a name=\"cs-riskfactor-eu-pcsp-28.461\"> </a></td><td>RT to a vol exposing the uterus only female</td><td>RT to a vol exposing the uterus only female</td></tr><tr><td style=\"white-space:nowrap\">29.1<a name=\"cs-riskfactor-eu-pcsp-29.461\"> </a></td><td>RT to a vol exposing the oral cavity or salivary glands</td><td>RT to a vol exposing the oral cavity or salivary glands</td></tr><tr><td style=\"white-space:nowrap\">29.4<a name=\"cs-riskfactor-eu-pcsp-29.464\"> </a></td><td>Chemotherapy</td><td>Chemotherapy</td></tr><tr><td style=\"white-space:nowrap\">30.1<a name=\"cs-riskfactor-eu-pcsp-30.461\"> </a></td><td>RT to a vol exposing the gastro-intestinal tract</td><td>RT to a vol exposing the gastro-intestinal tract</td></tr><tr><td style=\"white-space:nowrap\">30.3<a name=\"cs-riskfactor-eu-pcsp-30.463\"> </a></td><td>Oesophageal surgery</td><td>Oesophageal surgery</td></tr><tr><td style=\"white-space:nowrap\">30.4<a name=\"cs-riskfactor-eu-pcsp-30.464\"> </a></td><td>Abdominal surgery</td><td>Abdominal surgery</td></tr><tr><td style=\"white-space:nowrap\">30.5<a name=\"cs-riskfactor-eu-pcsp-30.465\"> </a></td><td>With a history of chronic GVHD</td><td>With a history of chronic GVHD</td></tr><tr><td style=\"white-space:nowrap\">31.1<a name=\"cs-riskfactor-eu-pcsp-31.461\"> </a></td><td>Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2</td><td>Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">32.1<a name=\"cs-riskfactor-eu-pcsp-32.461\"> </a></td><td>RT to a vol exposing the lungs</td><td>RT to a vol exposing the lungs</td></tr><tr><td style=\"white-space:nowrap\">32.3<a name=\"cs-riskfactor-eu-pcsp-32.463\"> </a></td><td>Bleomycin</td><td>Bleomycin</td></tr><tr><td style=\"white-space:nowrap\">32.4<a name=\"cs-riskfactor-eu-pcsp-32.464\"> </a></td><td>Busulfan</td><td>Busulfan</td></tr><tr><td style=\"white-space:nowrap\">32.5<a name=\"cs-riskfactor-eu-pcsp-32.465\"> </a></td><td>BCNU Carmustine</td><td>BCNU Carmustine</td></tr><tr><td style=\"white-space:nowrap\">32.6<a name=\"cs-riskfactor-eu-pcsp-32.466\"> </a></td><td>CCNU Lomustine</td><td>CCNU Lomustine</td></tr><tr><td style=\"white-space:nowrap\">32.7<a name=\"cs-riskfactor-eu-pcsp-32.467\"> </a></td><td>Thoracic surgery</td><td>Thoracic surgery</td></tr><tr><td style=\"white-space:nowrap\">33.1<a name=\"cs-riskfactor-eu-pcsp-33.461\"> </a></td><td>Cisplatin Any dose</td><td>Cisplatin Any dose</td></tr><tr><td style=\"white-space:nowrap\">33.2<a name=\"cs-riskfactor-eu-pcsp-33.462\"> </a></td><td>Ifosfamide Any dose</td><td>Ifosfamide Any dose</td></tr><tr><td style=\"white-space:nowrap\">33.3<a name=\"cs-riskfactor-eu-pcsp-33.463\"> </a></td><td>Carboplatin Any dose</td><td>Carboplatin Any dose</td></tr><tr><td style=\"white-space:nowrap\">34.1<a name=\"cs-riskfactor-eu-pcsp-34.461\"> </a></td><td>RT to a volume exposing the liver</td><td>RT to a volume exposing the liver</td></tr><tr><td style=\"white-space:nowrap\">34.10<a name=\"cs-riskfactor-eu-pcsp-34.4610\"> </a></td><td>Chronic GVHD</td><td>Chronic GVHD</td></tr><tr><td style=\"white-space:nowrap\">34.11<a name=\"cs-riskfactor-eu-pcsp-34.4611\"> </a></td><td>Liver surgery</td><td>Liver surgery</td></tr><tr><td style=\"white-space:nowrap\">34.3<a name=\"cs-riskfactor-eu-pcsp-34.463\"> </a></td><td>HSCT (irrespective of GVHD)</td><td>HSCT (irrespective of GVHD)</td></tr><tr><td style=\"white-space:nowrap\">34.5<a name=\"cs-riskfactor-eu-pcsp-34.465\"> </a></td><td>Mercaptopurine Thioguanine</td><td>Mercaptopurine Thioguanine</td></tr><tr><td style=\"white-space:nowrap\">34.6<a name=\"cs-riskfactor-eu-pcsp-34.466\"> </a></td><td>Dactinomycin</td><td>Dactinomycin</td></tr><tr><td style=\"white-space:nowrap\">34.8<a name=\"cs-riskfactor-eu-pcsp-34.468\"> </a></td><td>Chronic viral hepatitis</td><td>Chronic viral hepatitis</td></tr><tr><td style=\"white-space:nowrap\">34.9<a name=\"cs-riskfactor-eu-pcsp-34.469\"> </a></td><td>Sinusoidal obstruction syndrome</td><td>Sinusoidal obstruction syndrome</td></tr><tr><td style=\"white-space:nowrap\">35.1<a name=\"cs-riskfactor-eu-pcsp-35.461\"> </a></td><td>HSCT (irrespective of GVHD)</td><td>HSCT (irrespective of GVHD)</td></tr><tr><td style=\"white-space:nowrap\">35.2<a name=\"cs-riskfactor-eu-pcsp-35.462\"> </a></td><td>Multiple red blood cell transfusions</td><td>Multiple red blood cell transfusions</td></tr><tr><td style=\"white-space:nowrap\">36.1<a name=\"cs-riskfactor-eu-pcsp-36.461\"> </a></td><td>Splenectomy</td><td>Splenectomy</td></tr><tr><td style=\"white-space:nowrap\">36.2<a name=\"cs-riskfactor-eu-pcsp-36.462\"> </a></td><td>RT >= 10 Gy to a vol exposing the spleen</td><td>RT >= 10 Gy to a vol exposing the spleen</td></tr><tr><td style=\"white-space:nowrap\">36.3<a name=\"cs-riskfactor-eu-pcsp-36.463\"> </a></td><td>Allogenic HSCT (with or without TBI)</td><td>Allogenic HSCT (with or without TBI)</td></tr><tr><td style=\"white-space:nowrap\">36.4<a name=\"cs-riskfactor-eu-pcsp-36.464\"> </a></td><td>Autologus HSCT conditioned with TBI</td><td>Autologus HSCT conditioned with TBI</td></tr><tr><td style=\"white-space:nowrap\">37.1<a name=\"cs-riskfactor-eu-pcsp-37.461\"> </a></td><td>Hereditary cancer sd</td><td>Hereditary cancer sd</td></tr><tr><td style=\"white-space:nowrap\">38.1<a name=\"cs-riskfactor-eu-pcsp-38.461\"> </a></td><td>Any RT including TBI (predominantly in the RT field)</td><td>Any RT including TBI (predominantly in the RT field)</td></tr><tr><td style=\"white-space:nowrap\">38.2<a name=\"cs-riskfactor-eu-pcsp-38.462\"> </a></td><td>HSCT Especially with a history of skin GvHD</td><td>HSCT Especially with a history of skin GvHD</td></tr><tr><td style=\"white-space:nowrap\">39.1<a name=\"cs-riskfactor-eu-pcsp-39.461\"> </a></td><td>RT to a vol exposing the colon and rectum</td><td>RT to a vol exposing the colon and rectum</td></tr><tr><td style=\"white-space:nowrap\">40.1<a name=\"cs-riskfactor-eu-pcsp-40.461\"> </a></td><td>RT to a vol exposing the oral cavity</td><td>RT to a vol exposing the oral cavity</td></tr><tr><td style=\"white-space:nowrap\">41.2<a name=\"cs-riskfactor-eu-pcsp-41.462\"> </a></td><td>Anthracyclines and/or Mitoxantrone</td><td>Anthracyclines and/or Mitoxantrone</td></tr><tr><td style=\"white-space:nowrap\">41.3<a name=\"cs-riskfactor-eu-pcsp-41.463\"> </a></td><td>Epipodophyllotoxins or autologous</td><td>Epipodophyllotoxins or autologous</td></tr><tr><td style=\"white-space:nowrap\">41.4<a name=\"cs-riskfactor-eu-pcsp-41.464\"> </a></td><td>Autologous haematopoietic stem cell transplant</td><td>Autologous haematopoietic stem cell transplant</td></tr><tr><td style=\"white-space:nowrap\">42.1<a name=\"cs-riskfactor-eu-pcsp-42.461\"> </a></td><td>Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)</td><td>Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)</td></tr><tr><td style=\"white-space:nowrap\">45.1<a name=\"cs-riskfactor-eu-pcsp-45.461\"> </a></td><td>RT to a vol exposing the head or brain</td><td>RT to a vol exposing the head or brain</td></tr><tr><td style=\"white-space:nowrap\">46.1<a name=\"cs-riskfactor-eu-pcsp-46.461\"> </a></td><td>RT between 15 and 35 Gy to a vol exposing the heart</td><td>RT between 15 and 35 Gy to a vol exposing the heart</td></tr><tr><td style=\"white-space:nowrap\">46.2<a name=\"cs-riskfactor-eu-pcsp-46.462\"> </a></td><td>Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2</td><td>Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">47.1<a name=\"cs-riskfactor-eu-pcsp-47.461\"> </a></td><td>RT to a vol exposing the kidney or urinary tract</td><td>RT to a vol exposing the kidney or urinary tract</td></tr></table></div>" ] ; # fhir:url [ fhir:v "http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp"^^xsd:anyURI] ; # fhir:version [ fhir:v "0.2.0"] ; # fhir:name [ fhir:v "CsRiskFactorPcsp"] ; # fhir:title [ fhir:v "Risk Factors"] ; # fhir:status [ fhir:v "draft"] ; # fhir:experimental [ fhir:v "false"^^xsd:boolean] ; # fhir:date [ fhir:v "2024-12-11T15:09:45+00:00"^^xsd:dateTime] ; # fhir:publisher [ fhir:v "PanCareSurPass Project"] ; # fhir:contact ( [ fhir:name [ fhir:v "PanCareSurPass Project" ] ; ( fhir:telecom [ fhir:system [ fhir:v "url" ] ; fhir:value [ fhir:v "https://www.pancaresurpass.eu/" ] ] ) ] [ fhir:name [ fhir:v "PanCareSurPass Project" ] ; ( fhir:telecom [ fhir:system [ fhir:v "url" ] ; fhir:value [ fhir:v "https://www.pancaresurpass.eu/" ] ] ) ] ) ; # fhir:description [ fhir:v "Risk Factors used by the PCSP algorithm"] ; # fhir:jurisdiction ( [ ( fhir:coding [ fhir:system [ fhir:v "http://unstats.un.org/unsd/methods/m49/m49.htm"^^xsd:anyURI ] ; fhir:code [ fhir:v "150" ] ; fhir:display [ fhir:v "Europe" ] ] ) ] ) ; # fhir:caseSensitive [ fhir:v "true"^^xsd:boolean] ; # fhir:content [ fhir:v "complete"] ; # fhir:count [ fhir:v "112"^^xsd:nonNegativeInteger] ; # fhir:concept ( [ fhir:code [ fhir:v "1.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the thyroid gland" ] ; fhir:definition [ fhir:v "RT to a vol exposing the thyroid gland" ] ] [ fhir:code [ fhir:v "1.2" ] ; fhir:display [ fhir:v "TBI" ] ; fhir:definition [ fhir:v "TBI" ] ] [ fhir:code [ fhir:v "1.3" ] ; fhir:display [ fhir:v "MIBG therapy (I-131 MIBG therapy)" ] ; fhir:definition [ fhir:v "MIBG therapy (I-131 MIBG therapy)" ] ] [ fhir:code [ fhir:v "2.1" ] ; fhir:display [ fhir:v "RT >= 10 Gy to a vol exposing the breasts" ] ; fhir:definition [ fhir:v "RT >= 10 Gy to a vol exposing the breasts" ] ] [ fhir:code [ fhir:v "2.2" ] ; fhir:display [ fhir:v "OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age" ] ; fhir:definition [ fhir:v "OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age" ] ] [ fhir:code [ fhir:v "3.1" ] ; fhir:display [ fhir:v "RT >= 35 Gy to a vol exposing the heart" ] ; fhir:definition [ fhir:v "RT >= 35 Gy to a vol exposing the heart" ] ] [ fhir:code [ fhir:v "3.2" ] ; fhir:display [ fhir:v "Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2" ] ; fhir:definition [ fhir:v "Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2" ] ] [ fhir:code [ fhir:v "3.3" ] ; fhir:display [ fhir:v "RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2" ] ; fhir:definition [ fhir:v "RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2" ] ] [ fhir:code [ fhir:v "4.1" ] ; fhir:display [ fhir:v "Alkylating agents" ] ; fhir:definition [ fhir:v "Alkylating agents" ] ] [ fhir:code [ fhir:v "4.2" ] ; fhir:display [ fhir:v "RT to a vol exposing the testes" ] ; fhir:definition [ fhir:v "RT to a vol exposing the testes" ] ] [ fhir:code [ fhir:v "4.3" ] ; fhir:display [ fhir:v "Including TBI" ] ; fhir:definition [ fhir:v "Including TBI" ] ] [ fhir:code [ fhir:v "5.1" ] ; fhir:display [ fhir:v "RT >=12 Gy to a vol exposing the testicles" ] ; fhir:definition [ fhir:v "RT >=12 Gy to a vol exposing the testicles" ] ] [ fhir:code [ fhir:v "6.3" ] ; fhir:display [ fhir:v "Surgery to the spinal cord, sympathetic nerves or pelvis" ] ; fhir:definition [ fhir:v "Surgery to the spinal cord, sympathetic nerves or pelvis" ] ] [ fhir:code [ fhir:v "6.4" ] ; fhir:display [ fhir:v "Hypogonadal" ] ; fhir:definition [ fhir:v "Hypogonadal" ] ] [ fhir:code [ fhir:v "7.2" ] ; fhir:display [ fhir:v "RT to a vol exposing the ovaries" ] ; fhir:definition [ fhir:v "RT to a vol exposing the ovaries" ] ] [ fhir:code [ fhir:v "8.1" ] ; fhir:display [ fhir:v "RT >= 30 Gy to a vol exposing the head or the brain" ] ; fhir:definition [ fhir:v "RT >= 30 Gy to a vol exposing the head or the brain" ] ] [ fhir:code [ fhir:v "8.2" ] ; fhir:display [ fhir:v "Cisplatin (with or without carboplatin > 1500 mg/m2)" ] ; fhir:definition [ fhir:v "Cisplatin (with or without carboplatin > 1500 mg/m2)" ] ] [ fhir:code [ fhir:v "9.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the pancreas" ] ; fhir:definition [ fhir:v "RT to a vol exposing the pancreas" ] ] [ fhir:code [ fhir:v "10.2" ] ; fhir:display [ fhir:v "HSCT" ] ; fhir:definition [ fhir:v "HSCT" ] ] [ fhir:code [ fhir:v "11.1" ] ; fhir:display [ fhir:v "RT to a volume exposing the hypothalamus or pituatary gland" ] ; fhir:definition [ fhir:v "RT to a volume exposing the hypothalamus or pituatary gland" ] ] [ fhir:code [ fhir:v "11.3" ] ; fhir:display [ fhir:v "Hypothalamic or pituitary tumour" ] ; fhir:definition [ fhir:v "Hypothalamic or pituitary tumour" ] ] [ fhir:code [ fhir:v "11.4" ] ; fhir:display [ fhir:v "Neurosurgery of the hypothalamus or pituitary gland" ] ; fhir:definition [ fhir:v "Neurosurgery of the hypothalamus or pituitary gland" ] ] [ fhir:code [ fhir:v "12.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the kidneys, heart and associated large vessels" ] ; fhir:definition [ fhir:v "RT to a vol exposing the kidneys, heart and associated large vessels" ] ] [ fhir:code [ fhir:v "12.3" ] ; fhir:display [ fhir:v "Nephrectomy" ] ; fhir:definition [ fhir:v "Nephrectomy" ] ] [ fhir:code [ fhir:v "12.4" ] ; fhir:display [ fhir:v "Ifosfamide" ] ; fhir:definition [ fhir:v "Ifosfamide" ] ] [ fhir:code [ fhir:v "12.5" ] ; fhir:display [ fhir:v "Platinium based chemotherapy" ] ; fhir:definition [ fhir:v "Platinium based chemotherapy" ] ] [ fhir:code [ fhir:v "12.6" ] ; fhir:display [ fhir:v "Nitrosureas" ] ; fhir:definition [ fhir:v "Nitrosureas" ] ] [ fhir:code [ fhir:v "12.7" ] ; fhir:display [ fhir:v "Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)" ] ; fhir:definition [ fhir:v "Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)" ] ] [ fhir:code [ fhir:v "13.1" ] ; fhir:display [ fhir:v "Cranial and/or spinal RT" ] ; fhir:definition [ fhir:v "Cranial and/or spinal RT" ] ] [ fhir:code [ fhir:v "13.3" ] ; fhir:display [ fhir:v "Methotrexate" ] ; fhir:definition [ fhir:v "Methotrexate" ] ] [ fhir:code [ fhir:v "13.4" ] ; fhir:display [ fhir:v "Gonadal failure" ] ; fhir:definition [ fhir:v "Gonadal failure" ] ] [ fhir:code [ fhir:v "13.5" ] ; fhir:display [ fhir:v "Growth hormone deficiency" ] ; fhir:definition [ fhir:v "Growth hormone deficiency" ] ] [ fhir:code [ fhir:v "13.6" ] ; fhir:display [ fhir:v "Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment" ] ; fhir:definition [ fhir:v "Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment" ] ] [ fhir:code [ fhir:v "13.7" ] ; fhir:display [ fhir:v "HSCT, especially with an history of GVHD" ] ; fhir:definition [ fhir:v "HSCT, especially with an history of GVHD" ] ] [ fhir:code [ fhir:v "14.3" ] ; fhir:display [ fhir:v "High dose RT" ] ; fhir:definition [ fhir:v "High dose RT" ] ] [ fhir:code [ fhir:v "15.1" ] ; fhir:display [ fhir:v "Radiotherapy to a vol exposing the HP region >= 30 Gy" ] ; fhir:definition [ fhir:v "Radiotherapy to a vol exposing the HP region >= 30 Gy" ] ] [ fhir:code [ fhir:v "15.2" ] ; fhir:display [ fhir:v "Surgery near or within the HP region" ] ; fhir:definition [ fhir:v "Surgery near or within the HP region" ] ] [ fhir:code [ fhir:v "15.3" ] ; fhir:display [ fhir:v "CNS tumours near or within the HP region" ] ; fhir:definition [ fhir:v "CNS tumours near or within the HP region" ] ] [ fhir:code [ fhir:v "16.1" ] ; fhir:display [ fhir:v "Radiotherapy to a vol exposing the HP region< 30 Gy" ] ; fhir:definition [ fhir:v "Radiotherapy to a vol exposing the HP region< 30 Gy" ] ] [ fhir:code [ fhir:v "16.2" ] ; fhir:display [ fhir:v "Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)" ] ; fhir:definition [ fhir:v "Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)" ] ] [ fhir:code [ fhir:v "17.1" ] ; fhir:display [ fhir:v "Radiotherapy to a vol exposing the HP region" ] ; fhir:definition [ fhir:v "Radiotherapy to a vol exposing the HP region" ] ] [ fhir:code [ fhir:v "17.5" ] ; fhir:display [ fhir:v "hydrocephalus or cerebrospinal fluid shunt" ] ; fhir:definition [ fhir:v "hydrocephalus or cerebrospinal fluid shunt" ] ] [ fhir:code [ fhir:v "19.3" ] ; fhir:display [ fhir:v "Radioiodine therapy (I-131 ablation therapy)" ] ; fhir:definition [ fhir:v "Radioiodine therapy (I-131 ablation therapy)" ] ] [ fhir:code [ fhir:v "19.5" ] ; fhir:display [ fhir:v "Allogenic HSCT" ] ; fhir:definition [ fhir:v "Allogenic HSCT" ] ] [ fhir:code [ fhir:v "19.6" ] ; fhir:display [ fhir:v "Total thyroidectomy" ] ; fhir:definition [ fhir:v "Total thyroidectomy" ] ] [ fhir:code [ fhir:v "20.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the head, brain or neck" ] ; fhir:definition [ fhir:v "RT to a vol exposing the head, brain or neck" ] ] [ fhir:code [ fhir:v "21.1" ] ; fhir:display [ fhir:v "History of a central nervous system tumor" ] ; fhir:definition [ fhir:v "History of a central nervous system tumor" ] ] [ fhir:code [ fhir:v "21.2" ] ; fhir:display [ fhir:v "RT to a vol exposing the brain ANY DOSE" ] ; fhir:definition [ fhir:v "RT to a vol exposing the brain ANY DOSE" ] ] [ fhir:code [ fhir:v "21.4" ] ; fhir:display [ fhir:v "Brain surgery" ] ; fhir:definition [ fhir:v "Brain surgery" ] ] [ fhir:code [ fhir:v "21.5" ] ; fhir:display [ fhir:v "High dose cytarabine IV (intravenous)" ] ; fhir:definition [ fhir:v "High dose cytarabine IV (intravenous)" ] ] [ fhir:code [ fhir:v "21.6" ] ; fhir:display [ fhir:v "High dose MTX IV" ] ; fhir:definition [ fhir:v "High dose MTX IV" ] ] [ fhir:code [ fhir:v "21.7" ] ; fhir:display [ fhir:v "Any Chemotherapy IT (intrathecal)" ] ; fhir:definition [ fhir:v "Any Chemotherapy IT (intrathecal)" ] ] [ fhir:code [ fhir:v "22.1" ] ; fhir:display [ fhir:v "Vinca-Alkaloids" ] ; fhir:definition [ fhir:v "Vinca-Alkaloids" ] ] [ fhir:code [ fhir:v "22.2" ] ; fhir:display [ fhir:v "Cisplatin or carboplatin" ] ; fhir:definition [ fhir:v "Cisplatin or carboplatin" ] ] [ fhir:code [ fhir:v "23.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the lens" ] ; fhir:definition [ fhir:v "RT to a vol exposing the lens" ] ] [ fhir:code [ fhir:v "24.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the eye and orbit" ] ; fhir:definition [ fhir:v "RT to a vol exposing the eye and orbit" ] ] [ fhir:code [ fhir:v "25.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the craniofacial area, especially after high doses and at a young age" ] ; fhir:definition [ fhir:v "RT to a vol exposing the craniofacial area, especially after high doses and at a young age" ] ] [ fhir:code [ fhir:v "25.3" ] ; fhir:display [ fhir:v "Surgery to the face, especially at a young age" ] ; fhir:definition [ fhir:v "Surgery to the face, especially at a young age" ] ] [ fhir:code [ fhir:v "26.1" ] ; fhir:display [ fhir:v "Surgery of the spine" ] ; fhir:definition [ fhir:v "Surgery of the spine" ] ] [ fhir:code [ fhir:v "26.2" ] ; fhir:display [ fhir:v "Surgery of the chest (Does not include CVC pose)" ] ; fhir:definition [ fhir:v "Surgery of the chest (Does not include CVC pose)" ] ] [ fhir:code [ fhir:v "26.3" ] ; fhir:display [ fhir:v "RT to a vol exposing the spine" ] ; fhir:definition [ fhir:v "RT to a vol exposing the spine" ] ] [ fhir:code [ fhir:v "26.4" ] ; fhir:display [ fhir:v "Spinal or paraspinal malignancies" ] ; fhir:definition [ fhir:v "Spinal or paraspinal malignancies" ] ] [ fhir:code [ fhir:v "27.1" ] ; fhir:display [ fhir:v "Cyclophosphamide" ] ; fhir:definition [ fhir:v "Cyclophosphamide" ] ] [ fhir:code [ fhir:v "27.3" ] ; fhir:display [ fhir:v "RT to a vol exposing the bladder" ] ; fhir:definition [ fhir:v "RT to a vol exposing the bladder" ] ] [ fhir:code [ fhir:v "27.5" ] ; fhir:display [ fhir:v "Cystectomy" ] ; fhir:definition [ fhir:v "Cystectomy" ] ] [ fhir:code [ fhir:v "27.6" ] ; fhir:display [ fhir:v "Hysterectomy" ] ; fhir:definition [ fhir:v "Hysterectomy" ] ] [ fhir:code [ fhir:v "27.7" ] ; fhir:display [ fhir:v "Pelvic surgery" ] ; fhir:definition [ fhir:v "Pelvic surgery" ] ] [ fhir:code [ fhir:v "27.8" ] ; fhir:display [ fhir:v "Spinal cord surgery" ] ; fhir:definition [ fhir:v "Spinal cord surgery" ] ] [ fhir:code [ fhir:v "28.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the uterus only female" ] ; fhir:definition [ fhir:v "RT to a vol exposing the uterus only female" ] ] [ fhir:code [ fhir:v "29.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the oral cavity or salivary glands" ] ; fhir:definition [ fhir:v "RT to a vol exposing the oral cavity or salivary glands" ] ] [ fhir:code [ fhir:v "29.4" ] ; fhir:display [ fhir:v "Chemotherapy" ] ; fhir:definition [ fhir:v "Chemotherapy" ] ] [ fhir:code [ fhir:v "30.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the gastro-intestinal tract" ] ; fhir:definition [ fhir:v "RT to a vol exposing the gastro-intestinal tract" ] ] [ fhir:code [ fhir:v "30.3" ] ; fhir:display [ fhir:v "Oesophageal surgery" ] ; fhir:definition [ fhir:v "Oesophageal surgery" ] ] [ fhir:code [ fhir:v "30.4" ] ; fhir:display [ fhir:v "Abdominal surgery" ] ; fhir:definition [ fhir:v "Abdominal surgery" ] ] [ fhir:code [ fhir:v "30.5" ] ; fhir:display [ fhir:v "With a history of chronic GVHD" ] ; fhir:definition [ fhir:v "With a history of chronic GVHD" ] ] [ fhir:code [ fhir:v "31.1" ] ; fhir:display [ fhir:v "Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2" ] ; fhir:definition [ fhir:v "Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2" ] ] [ fhir:code [ fhir:v "32.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the lungs" ] ; fhir:definition [ fhir:v "RT to a vol exposing the lungs" ] ] [ fhir:code [ fhir:v "32.3" ] ; fhir:display [ fhir:v "Bleomycin" ] ; fhir:definition [ fhir:v "Bleomycin" ] ] [ fhir:code [ fhir:v "32.4" ] ; fhir:display [ fhir:v "Busulfan" ] ; fhir:definition [ fhir:v "Busulfan" ] ] [ fhir:code [ fhir:v "32.5" ] ; fhir:display [ fhir:v "BCNU Carmustine" ] ; fhir:definition [ fhir:v "BCNU Carmustine" ] ] [ fhir:code [ fhir:v "32.6" ] ; fhir:display [ fhir:v "CCNU Lomustine" ] ; fhir:definition [ fhir:v "CCNU Lomustine" ] ] [ fhir:code [ fhir:v "32.7" ] ; fhir:display [ fhir:v "Thoracic surgery" ] ; fhir:definition [ fhir:v "Thoracic surgery" ] ] [ fhir:code [ fhir:v "33.1" ] ; fhir:display [ fhir:v "Cisplatin Any dose" ] ; fhir:definition [ fhir:v "Cisplatin Any dose" ] ] [ fhir:code [ fhir:v "33.2" ] ; fhir:display [ fhir:v "Ifosfamide Any dose" ] ; fhir:definition [ fhir:v "Ifosfamide Any dose" ] ] [ fhir:code [ fhir:v "33.3" ] ; fhir:display [ fhir:v "Carboplatin Any dose" ] ; fhir:definition [ fhir:v "Carboplatin Any dose" ] ] [ fhir:code [ fhir:v "34.1" ] ; fhir:display [ fhir:v "RT to a volume exposing the liver" ] ; fhir:definition [ fhir:v "RT to a volume exposing the liver" ] ] [ fhir:code [ fhir:v "34.10" ] ; fhir:display [ fhir:v "Chronic GVHD" ] ; fhir:definition [ fhir:v "Chronic GVHD" ] ] [ fhir:code [ fhir:v "34.11" ] ; fhir:display [ fhir:v "Liver surgery" ] ; fhir:definition [ fhir:v "Liver surgery" ] ] [ fhir:code [ fhir:v "34.3" ] ; fhir:display [ fhir:v "HSCT (irrespective of GVHD)" ] ; fhir:definition [ fhir:v "HSCT (irrespective of GVHD)" ] ] [ fhir:code [ fhir:v "34.5" ] ; fhir:display [ fhir:v "Mercaptopurine Thioguanine" ] ; fhir:definition [ fhir:v "Mercaptopurine Thioguanine" ] ] [ fhir:code [ fhir:v "34.6" ] ; fhir:display [ fhir:v "Dactinomycin" ] ; fhir:definition [ fhir:v "Dactinomycin" ] ] [ fhir:code [ fhir:v "34.8" ] ; fhir:display [ fhir:v "Chronic viral hepatitis" ] ; fhir:definition [ fhir:v "Chronic viral hepatitis" ] ] [ fhir:code [ fhir:v "34.9" ] ; fhir:display [ fhir:v "Sinusoidal obstruction syndrome" ] ; fhir:definition [ fhir:v "Sinusoidal obstruction syndrome" ] ] [ fhir:code [ fhir:v "35.1" ] ; fhir:display [ fhir:v "HSCT (irrespective of GVHD)" ] ; fhir:definition [ fhir:v "HSCT (irrespective of GVHD)" ] ] [ fhir:code [ fhir:v "35.2" ] ; fhir:display [ fhir:v "Multiple red blood cell transfusions" ] ; fhir:definition [ fhir:v "Multiple red blood cell transfusions" ] ] [ fhir:code [ fhir:v "36.1" ] ; fhir:display [ fhir:v "Splenectomy" ] ; fhir:definition [ fhir:v "Splenectomy" ] ] [ fhir:code [ fhir:v "36.2" ] ; fhir:display [ fhir:v "RT >= 10 Gy to a vol exposing the spleen" ] ; fhir:definition [ fhir:v "RT >= 10 Gy to a vol exposing the spleen" ] ] [ fhir:code [ fhir:v "36.3" ] ; fhir:display [ fhir:v "Allogenic HSCT (with or without TBI)" ] ; fhir:definition [ fhir:v "Allogenic HSCT (with or without TBI)" ] ] [ fhir:code [ fhir:v "36.4" ] ; fhir:display [ fhir:v "Autologus HSCT conditioned with TBI" ] ; fhir:definition [ fhir:v "Autologus HSCT conditioned with TBI" ] ] [ fhir:code [ fhir:v "37.1" ] ; fhir:display [ fhir:v "Hereditary cancer sd" ] ; fhir:definition [ fhir:v "Hereditary cancer sd" ] ] [ fhir:code [ fhir:v "38.1" ] ; fhir:display [ fhir:v "Any RT including TBI (predominantly in the RT field)" ] ; fhir:definition [ fhir:v "Any RT including TBI (predominantly in the RT field)" ] ] [ fhir:code [ fhir:v "38.2" ] ; fhir:display [ fhir:v "HSCT Especially with a history of skin GvHD" ] ; fhir:definition [ fhir:v "HSCT Especially with a history of skin GvHD" ] ] [ fhir:code [ fhir:v "39.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the colon and rectum" ] ; fhir:definition [ fhir:v "RT to a vol exposing the colon and rectum" ] ] [ fhir:code [ fhir:v "40.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the oral cavity" ] ; fhir:definition [ fhir:v "RT to a vol exposing the oral cavity" ] ] [ fhir:code [ fhir:v "41.2" ] ; fhir:display [ fhir:v "Anthracyclines and/or Mitoxantrone" ] ; fhir:definition [ fhir:v "Anthracyclines and/or Mitoxantrone" ] ] [ fhir:code [ fhir:v "41.3" ] ; fhir:display [ fhir:v "Epipodophyllotoxins or autologous" ] ; fhir:definition [ fhir:v "Epipodophyllotoxins or autologous" ] ] [ fhir:code [ fhir:v "41.4" ] ; fhir:display [ fhir:v "Autologous haematopoietic stem cell transplant" ] ; fhir:definition [ fhir:v "Autologous haematopoietic stem cell transplant" ] ] [ fhir:code [ fhir:v "42.1" ] ; fhir:display [ fhir:v "Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)" ] ; fhir:definition [ fhir:v "Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)" ] ] [ fhir:code [ fhir:v "45.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the head or brain" ] ; fhir:definition [ fhir:v "RT to a vol exposing the head or brain" ] ] [ fhir:code [ fhir:v "46.1" ] ; fhir:display [ fhir:v "RT between 15 and 35 Gy to a vol exposing the heart" ] ; fhir:definition [ fhir:v "RT between 15 and 35 Gy to a vol exposing the heart" ] ] [ fhir:code [ fhir:v "46.2" ] ; fhir:display [ fhir:v "Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2" ] ; fhir:definition [ fhir:v "Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2" ] ] [ fhir:code [ fhir:v "47.1" ] ; fhir:display [ fhir:v "RT to a vol exposing the kidney or urinary tract" ] ; fhir:definition [ fhir:v "RT to a vol exposing the kidney or urinary tract" ] ] ) . #
IG © 2021+ PanCareSurPass Project. Package hl7.eu.fhir.pcsp#0.2.0 based on FHIR 4.0.1. Generated 2024-12-11
Links: Table of Contents |
QA Report
The PanCareSurPass Research and Innovation Action has received funding from the European Union's Horizon 2020
research and innovation programme under grant agreement No. 899999.
